Juan Miguel Mosquera
A5046264445- Prostate Cancer Treatment and Research
- Cancer Genomics and Diagnostics
- Prostate Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Molecular Biology Techniques and Applications
- Cancer, Lipids, and Metabolism
- Genetic factors in colorectal cancer
- Epigenetics and DNA Methylation
- Cancer Cells and Metastasis
- Urinary and Genital Oncology Studies
- Cancer-related gene regulation
- Glutathione Transferases and Polymorphisms
- Health Systems, Economic Evaluations, Quality of Life
- Cancer-related molecular mechanisms research
- Radiomics and Machine Learning in Medical Imaging
- Neuroendocrine Tumor Research Advances
- Renal cell carcinoma treatment
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- PARP inhibition in cancer therapy
- Ubiquitin and proteasome pathways
- Microtubule and mitosis dynamics
- BRCA gene mutations in cancer
Cornell University
2016-2025
Presbyterian Hospital
2016-2025
Weill Cornell Medicine
2016-2025
New York Hospital Queens
2015-2025
NewYork–Presbyterian Hospital
2015-2025
Lander Institute
2016-2024
New York Genome Center
2022-2024
Texas Health Dallas
2019-2023
Universidad San Francisco de Quito
2022
Institute for Biomedicine
2021
Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent through several comprehensive profiling efforts, but little is known about impact this heterogeneity on clinical outcome. Here, we report and transcriptomic analysis 429 patients with castration-resistant (mCRPC) linked longitudinal outcomes, integrating findings from whole-exome, transcriptome, histologic analysis. For 128 treated a first-line next-generation androgen receptor signaling inhibitor (ARSI;...
Abstract Precision medicine is an approach that takes into account the influence of individuals' genes, environment, and lifestyle exposures to tailor interventions. Here, we describe development a robust precision cancer care platform integrates whole-exome sequencing with living biobank enables high-throughput drug screens on patient-derived tumor organoids. To date, 56 tumor-derived organoid cultures 19 xenograft (PDX) models have been established from 769 patients enrolled in...
The androgen receptor (AR) plays a central role in establishing an oncogenic cascade that drives prostate cancer progression. Some cancers escape dependence and are often associated with aggressive phenotype. oestrogen alpha (ERα) is expressed cancers, independent of AR status. However, the ERα remains elusive. Using combination chromatin immunoprecipitation (ChIP) RNA-sequencing data, we identified ERα-specific non-coding transcriptome signature. Among putatively ERα-regulated intergenic...
Abstract Prostate cancer is a common and clinically heterogeneous disease with marked variability in progression. The recent identification of gene fusions the 5′-untranslated region TMPRSS2 (21q22.3) ETS transcription factor family members, either ERG (21q22.2), ETV1 (7p21.2), or ETV4 (17q21), suggests mechanism for overexpression genes majority prostate cancers. In current study using fluorescence situ hybridization (FISH), we identified TMPRSS2:ERG rearrangements 49.2% 118 primary cancers...
On July 31, 2013, the Prostate Cancer Foundation assembled a working committee on molecular biology and pathologic classification of neuroendocrine (NE) differentiation in prostate cancer. New clinical data emerging from cancers treated by contemporary androgen deprivation therapies, as well primary lesions, have highlighted need for refinement diagnostic terminology to encompass full spectrum NE differentiation. The system consists of: Usual adenocarcinoma with differentiation; 2)...
Prostate cancer (PCA) is one of the most prevalent cancers and a major leading cause morbidity mortality in Western world. The TMPRSS2-ERG fusion was recently identified as common recurrent chromosomal aberration this malignancy. In our study, we interrogated broad spectrum benign, precursor, malignant prostatic lesions to assess status using multicolor interphase fluorescence situ hybridization assay. Samples from hospital-based cohorts consisted 237 clinically localized PCA, 34 hormone...
Abstract A major hurdle in the study of rare tumors is a lack existing preclinical models. Neuroendocrine prostate cancer an uncommon and aggressive histologic variant that may arise de novo or as mechanism treatment resistance patients with pre-existing castration-resistant cancer. There are few available models to neuroendocrine Here, we report generation characterization tumor organoids derived from needle biopsies metastatic lesions four patients. We demonstrate genomic, transcriptomic,...
<h3>Importance</h3> Understanding molecular mechanisms of response and resistance to anticancer therapies requires prospective patient follow-up clinical functional validation both common low-frequency mutations. We describe a whole-exome sequencing (WES) precision medicine trial focused on patients with advanced cancer. <h3>Objective</h3> To understand how WES data affect therapeutic decision making in cancer identify novel biomarkers response. <h3>Design, Setting, Patients</h3> Patients...
More potent targeting of the androgen receptor (AR) in advanced prostate cancer is driving an increased incidence neuroendocrine (NEPC), aggressive and treatment-resistant AR-negative variant. Its molecular pathogenesis remains poorly understood but appears to require TP53 RB1 aberration. We modeled development NEPC from conventional prostatic adenocarcinoma using a patient-derived xenograft found that placental gene PEG10 de-repressed during adaptive response AR interference subsequently...
Neuroendocrine prostate cancer (NEPC), also referred to as anaplastic cancer, is a lethal tumor that most commonly arises in late stages of adenocarcinoma (PCA) with predilection metastasize visceral organs. In the current study, we explore for evidence Aurora kinase A (AURKA) and N-myc (MYCN) gene abnormalities are harbingers treatment-related NEPC (t-NEPC). We studied primary tissue from 15 hormone naïve PCAs, 51 castration-resistant cancers, metastatic tumors 72 patients at different...
Abstract Purpose: Neuroendocrine prostate cancer (NEPC) is an aggressive variant of that may develop de novo or as a mechanism treatment resistance. N-myc capable driving NEPC progression. Alisertib inhibits the interaction between and its stabilizing factor Aurora-A, inhibiting signaling, suppressing tumor growth. Patients Methods: Sixty men were treated with alisertib 50 mg twice daily for 7 days every 21 days. Eligibility included metastatic at least one: small-cell neuroendocrine...
Abstract Spindle cell rhabdomyosarcoma (RMS) is a rare form of RMS with different clinical characteristics between children and adult patients. Its genetic hallmark remains unknown it debatable if there pathogenetic relationship the spindle so‐called sclerosing RMS. We studied two pediatric one by next generation RNA sequencing FusionSeq data analysis to detect novel fusions. An SRF‐NCOA2 fusion was detected in from posterior neck 7‐month‐old child. The matched tumor karyotype confirmed FISH...
Upper tract urothelial carcinoma (UTUC) is characterized by a distinctly aggressive clinical phenotype. To define the biological features driving this phenotype, we performed an integrated analysis of whole-exome and RNA sequencing UTUC. Here report several key insights from our molecular dissection disease: 1) Most UTUCs are luminal-papillary; 2) UTUC has T-cell depleted immune contexture; 3) High FGFR3 expression enriched in correlates with its microenvironment; 4) Sporadic lower total...
Loss of androgen receptor (AR) signaling dependence occurs in approximately 15%–20% advanced treatment-resistant prostate cancers, and this may manifest clinically as transformation from a adenocarcinoma histology to castration-resistant neuroendocrine cancer (CRPC-NE). The diagnosis CRPC-NE currently relies on metastatic tumor biopsy, which is invasive for patients sometimes challenging diagnose due morphologic heterogeneity. By studying whole-exome sequencing whole-genome bisulfite cell...
Histologic transformation to small cell neuroendocrine prostate cancer occurs in a subset of patients with advanced as mechanism treatment resistance. Rovalpituzumab tesirine (SC16LD6.5) is an antibody-drug conjugate that targets delta-like protein 3 (DLL3) and was initially developed for lung cancer. We found DLL3 expressed most the castration-resistant (CRPC-NE) (36 47, 76.6%) adenocarcinomas (7 56, 12.5%). It shows minimal no expression localized (1 194) benign (0 103). correlates marker...